

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-729

**CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)**

Clinical Pharmacology and Biopharmaceutics Comment

NDA:	21-729
Drug:	Aripiprazole Orally Disintegrating Tablet
Trade Name:	Abilify ODT Discmelt
Strengths:	— 10 mg, 15 mg, 20mg, 30 mg Oral Disintegrating Tablets
Applicant:	Bristol Myers Squibb
Indication:	Treatment of Schizophrenia
Submission Type:	Response to Approvable Letter
Submission Date:	12/12/05
OND Division:	DPP (HFD-130)
OCBP Division:	DCPB1 (HFD-860)
Reviewer:	Kofi A. Kumi, Ph.D.
Team Leader:	Raman Baweja, Ph.D.

Background

The sponsor submitted NDA 21-729 for Abilify Discmelt Orally Disintegrating Tablets on December 22, 2003. An Approvable letter was issued on October 22, 2004. In this correspondence, the sponsor has submitted complete response to questions/comments that were included in the Approvable letter. This comment is related to Question No. 10, which was provided by OCPB to be included in the Approvable letter.

Question: We request that you adopt the following dissolution method and specification

Apparatus: USP Apparatus II (Paddle)
Speed: 75 rpm
Media: pH 4 Acetate Buffer
Volume: 1000 mL

Specification: Q NLT — in 30 minutes

The sponsor has agreed to adopt the method but would like to adopt an interim dissolution specification of Q NLT — in 30 minutes instead of a specification Q NLT — in 30 minutes.

The sponsor's rationale for an interim specification is that the proposed specification has no clinical relevance because the dissolution specification for the tablet was Q NLT —. However, the proposed method for the ODT and that for the tablet are different. The dissolution method for the tablet is

Apparatus: USP Apparatus II (Paddle)
Speed: 60 rpm
Media: pH 1.2 USP Buffer
Volume: 1000 mL

The Abilify tablet method was not chosen as the dissolution method for Abilify Discmelt ODT due to rapid dissolution, high variability, and loss of discriminatory ability for detecting changes in the ODT. Also, the sponsor indicates that a Q NLT — would increase — requirement as compared to the frequency of — that would occur under the dissolution specification of Q NLT — in 30 minutes. The sponsor argues that a dissolution specification tighter than NLT —, in 30 minutes would not provide additional indication of product performance. Hence, the

sponsor is proposing an interim dissolution specification of Q NLT — in 30 minutes. A final dissolution specification would to be set for aripiprazole ODT once the sponsor gains experience in full-scale manufacturing of at least — batches.

Comment to Sponsor:

1. The sponsor's proposal for an interim specification of Q NLT — in 30 minutes is acceptable. However, the sponsor should provide full dissolution profiles for at least — batches or batches produced for 12 months, whichever comes first, and should also provide data indicating how many — would be performed if the specification is set at Q NLT — A final specification would be set after the data is provided and reviewed.
2. The sponsor should provide the data requested in #1 above within 16 months of the date of the action letter
3. Please forward comments 1 and 2 to sponsor.

Kofi A. Kumi, Ph.D. _____

RD/FT Initialed by Raman Baweja, Ph.D. _____

CC:NDA 21-729, HFD-130, HFD-860 (Mehta, Baweja, KumiK), EDR (Biopharm)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Kofi Kumi
2/22/2006 12:25:30 PM
BIOPHARMACEUTICS

Raman Baweja
2/22/2006 06:29:56 PM
BIOPHARMACEUTICS

Clinical Pharmacology and Biopharmaceutics Review

NDA: 21-729
Drug: Aripiprazole
Trade: Abilify™ ODT
Strengths: 10 mg, 15 mg, 20mg, 30 mg Oral Disintegrating Tablets
Applicant: Bristol Myers Squibb
Indication: Treatment of Schizophrenia
Submission Type: New Formulation
Related IND and NDA: IND 62, 181 and NDA 21-436
Submission Dates: 12/22/03, 3/31/04, 7/8/04, 8/4/04
OND Division: DNDP (HFD-120)
OCPB Division: DPE1 (HFD-860)
Reviewer: Kofi A. Kumi, Ph.D.
Team Leader (Acting): Sally Yasuda, Pharm.D.

1. Executive Summary	2
1.1 Recommendation	2
1.2 Phase 4 Commitments	2
1.3. Summary of Important Clinical Pharmacology and Biopharmaceutics Findings	2
2. Question Based Review.....	6
2.1. General Attributes	6
2.1.1. What pertinent regulatory background or history contributes to the current assessment of the clinical pharmacology and biopharmaceutics of this drug?	6
2.1.3. What are the proposed mechanism of action and therapeutic indication?.....	6
2.1.4. What are the proposed dosage(s) and route of administration?.....	6
2.2. General Clinical Pharmacology.....	7
2.2.1 What are the design features of the clinical pharmacology and clinical studies used to support dosing or claims?	7
2.2.2. Are the active moieties in the plasma (or other biological fluid) appropriately identified and measured to assess pharmacokinetic parameters and exposure response relationship?	7
2.2.3.1. What safety profiles were reported?.....	7
2.2.4. What are the Pharmacokinetic Characteristics of the Drug?.....	8
2.5.2. Are aripiprazole ODTs bioequivalent to the approved conventional tablets?.....	10
2.5.3. What data support or do not support a waiver of in vivo bioequivalence for the 10 mg, 15 mg and 20 mg ODT formulations?.....	12
2.5.4. What is the Proposed Dissolution Method and Specification for Aripiprazole ODT Formulations?.....	13
2.5.5. What dosing recommendations are necessary?	21
2.5.6. What is the effect of food on the bioavailability of aripiprazole?	21
2.5.7. Based on the Biopharmaceutics Classification System (BCS) principles, in what class is Aripiprazole?.....	21
2.6. Analytical Section.....	21
2.6.1. What analytical methods were used to identify aripiprazole and its metabolite, dehydro-aripiprazole?.....	21
3. Detailed Labeling Recommendations.....	21
4. Appendix	23
4.1. Package Insert	23
4.2. DSI Report.....	56
4.3. Individual Study Review	59
4.4. Cover sheet and OCPB filing/review form	111

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.